Omeza

Wounds unresponsive to Advanced Treatments for at least 7 months are healed with OCM?. "Omega Fatty Acid-Based Therapy for Healing of Recalcitrant Wounds in Patients with Complex Comorbidities." Advances in Skin & Wound Care?37(10):p 550-554, October 2024. https://lnkd.in/edUrg9D6

Gil paper from the University of Miami published in International Wound Journal showing OCMTM alone is able to decrease bacterial bioburden. Excerpt from manuscript: OCMTM treated wounds "exhibited a significant (p<0.05) bacterial reduction compared to all other treatment groups....MWM demonstrated promise in addressing colonized wounds with biofilms." https://lnkd.in/ejS4W2-Z

A Case Series of 63 hard to heal wounds treated with OCM TM supports use in multiple wound types of any duration. Swain-Cole article: Journal of Wound Care, Sept, 2024:33,9,S27-S35. https://lnkd.in/gHcNnAcD

Peer reviewed published study: A novel approach for the treatment of diabetic foot ulcers using a multimodal wound matrix: a clinical study Excerpt: "Of the 14 patients who completed the study, eight experienced complete closure of their DFUs and six experienced PARs of 73–99%. Among these, three experienced complete healing of their DFUs after four applications of wound matrix and offloading." Read full publication: https://lnkd.in/eAHqFYZF

OCM delivers excellent efficacy in DFUs: https://lnkd.in/eZxt8sDK A novel approach for the treatment of diabetic foot ulcers using a multimodal wound matrix: a clinical study. Of the 14 patients who completed the study, eight experienced complete closure of their DFUs and six experienced PARs of 73-99%. Among these, three experienced complete healing of their DFUs after four applications of wound matrix and offloading. Of the five patients in the study who had DFUs of >1 year's duration, three patients' DFUs completely healed by week 12 (the remaining two DFUs had 12-week PARs of 73% and 85%)

Omeza is a leader in wound healing, with the first drug-device product that reduces biofilm formation and inhibits microbial growth without the risk of developing antimicrobial resistance. Listen in to Cynthia L. Flowers discusses how the company is already pursuing multiple commercialization strategies with Medicare, the Veteran’s Affairs (VA), and the U.S. Department of Defense. Check out the prior videos on commercialization in case you missed it! OMEZA currently has the reimbursement code A2014 which can be added to any wound care procedure. The company is building upon clinical evidence with peer-reviewed publications to go to the private payor community, which they expect to have completed in the 4th quarter of 2024.

Omeza is in the beginning phases of commercializing OCM with plans to ramp up commercialization efforts with the Veteran’s Administration and U.S. Department of Defense. Listen in as OMEZA's CEO, Cynthia L. Flowers, discusses how the company's lead product, OCM, is already in 15 VA hospitals, with 5 more coming online shortly! OMEZA has several case studies from the VA where the company has assisted in the prevention of amputation in serious wound injuries. The company also plans to scale the commercial team to work in the payor community, hospitals, and office settings. But will Medicare and the payor community reimburse this product with so many options available? Stay tuned for an update on our reimbursement strategy by following us!

OMEZA's Complete Matrix is the lead drug-device product with 510(k) approval as a bioactive drug-device that reduces biofilm and treats all phases of wound healing, unlike other products currently available that only focus on one or two phases of wound healing. ? With so many other products out there already, ranging from devices, therapeutics, and dressings, there has been little to no innovation in this category for the past decade. Antibiotic resistance remains a key focus of innovation in the wound care space. Omeza plans to upend the wound care paradigm with the personalization of OCM and the ability of OCM to reduce biofilm formation and inhibit microbial growth without the risk of developing antimicrobial resistance. Stay tuned for an update on our commercialization plan by following us! ? #woundhealing #OMEZA

Listen in as Cynthia L. Flowers, CEO of Omeza, discusses the OMEZA Complete Matrix, or OCM. OCM is OMEZA’s lead drug-device product with FDA 510(k) approval as a bioactive drug-device that reduces biofilm and treats all phases of wound healing. ? With applications ranging from pressure ulcers, venous leg ulcers, diabetic foot ulcers, trauma and post-surgical wounds, and 1st and 2nd degree burns, OMEZA remains dedicated to providing a solution for the unmet need in wound care and remains excited for the future commercial application. How does OMEZA stack up to the competition? Stay tuned by following us here! #woundhealing #OMEZA

“We continue to be encouraged by the positive results we’re seeing in real-world settings and across clinical trials showing that OCM? addresses many of the challenges that are inherent to diabetic foot ulcers, but which other wound care treatments have been unable to overcome,” said Desmond Bell, DPM, Chief Medical Officer at Omeza?.?“We are continuing to evaluate OCM across many wound types and in multiple settings to replicate our findings and expand its usage to more patients whose unmet needs require a novel platform such as OCM?. READ FULL PRESS RELEASE: https://lnkd.in/eD8pGpk2